Health5 months ago
US tariffs and MFN pricing threaten pharma investment and access in Europe
Rising uncertainty driven by US tariffs and proposed “most-favoured nation” pricing is prompting pharmaceutical companies to delay investment and product launches in Europe. US tariffs and...
